Efficacy of Light-Activated Anti-Microbial Fabrics against Human Pathogens
Efficacy of Light-Activated Anti-Microbial Fabrics against Human Pathogens
批准号:
7907150
负责人:
Elizabeth Anne Ramsburg
金额:
$10.0万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2011
资助国家:
美国
项目状态:
已结题
起止时间:
2011-09-01 至 2012-02-29
中文摘要
描述(由申请人提供):
英文摘要
DESCRIPTION (provided by applicant):
Project Summary/Abstract The Specific Aim of this proposal is to test the efficacy of Light-Activated Anti-Microbial fabrics to biologically inactivate three model pathogens, influenza H1N1 swine, respiratory syncytial virus (RSV) and cowpox virus (as a surrogate for variola virus). These viruses are pathogenic to humans and spread rapidly from infected to uninfected individuals. The World Health Organization estimates that influenza epidemics cost the US economy $71-167 billion per year and that 250,000-500,000 people die every year from influenza. RSV poses a severe and continual health risk to children and the elderly, especially in a hospital setting. Variola virus, although eradicated in the general population since 1977, still poses a deadly threat as a bioterrorism agent. Prevention of the spread of infectious viruses is largely accomplished through isolation of infected patients away from the general population. The use of personal protective equipment (PPE), such as respirator masks and gloves, is currently the most effective way that health care workers can protect themselves. However standard contaminated PPE also can serve as effective modes of microorganism transmission when worn by health care workers treating multiple patients. Using a proprietary technology, LaamScience has developed coatings for a durable, self-decontaminating, and cost-effective N95 respirator mask that inactivate a broad spectrum of enveloped viruses and bacteria. The coating contains a Light-Activated Anti-Microbial (LAAM) dye that emits a reactive oxygen species, singlet oxygen, when exposed to light. Singlet oxygen is highly effective at inactivating viruses and killing bacteria. We have shown efficacy against influenza virus strains as well as staphylococci under normal room light conditions, with inactivation measured in minutes rather than the hours required with traditional antimicrobial agents. The proposed Phase I work will address the potential of the LaamScience coated fabric to inactivate Influenza, RSV and cowpox virus, as evidence to support the use of coated masks in healthcare settings, and more generally in the event of the release of a bioterrorism agent. The milestones of this work are to demonstrate the ability of the anti-microbial to inactivate cowpox virus (as a model for smallpox), Influenza H1N1 swine, and RSV. We will confirm that the virus inactivation is irreversible and occurs in a practical window of time under indoor lighting conditions. Accomplishment of these milestones will allow testing of real-world applications of the fabric coating against these viruses as well as against additional pathogens, which will be the goal of the Phase II studies.
PUBLIC HEALTH RELEVANCE:
Project Narrative - Public Health Relevance The World Health Organization estimates that influenza epidemics cost the US economy $71-167 billion per year and that 250,000-500,000 people die every year from influenza. Groups most at risk are health care workers, patients, young people, and the geriatric population. In closed settings, (e.g., hospitals, child-care centers, military barracks, college dormitories, nursing homes) infections spread rapidly. Viral threats also include intentional spreading of deadly viruses, such as smallpox, as bioterrorism agents. Thus, new, multiple measures are needed to decrease infection rates and protect against bioterrorism threats. The LaamScience fabric coating will serve as a decontamination agent on personal protective equipment such as respirator masks and will reduce the danger of transmission of pathogenic agents between individuals.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Neutralizing Antibody Induction by Centralized Genes
-
批准号:7756630
-
项目类别:
-
资助金额:$45.15万
-
财政年份:2009
-
负责人:Elizabeth Anne Ramsburg
-
依托单位:
Vaccine Vector Comparison Study
-
批准号:7652093
-
项目类别:
-
资助金额:$26.94万
-
财政年份:2008
-
负责人:Elizabeth Anne Ramsburg
-
依托单位:
国内基金
海外基金
登录
查看更多内容
上调间充质干细胞LIGHT、IL-21及
Sig lec-10用于卵巢癌免疫协同增效治疗
的多模态影像学研究
-
批准号:
-
项目类别:省市级项目
-
资助金额:10.0万元
-
批准年份:2025
-
负责人:曹明慧
-
依托单位:
LIGHT/HVEM-亮氨酸轴异常引起蜕膜基质细胞过度衰老致复发流产的机制研究
-
批准号:32370914
-
项目类别:面上项目
-
资助金额:50万元
-
批准年份:2023
-
负责人:李明清
-
依托单位:
LIGHT促NLRP3炎症小体活化介导他克莫司所致肾纤维化的作用机制研究
-
批准号:82300855
-
项目类别:青年科学基金项目
-
资助金额:30万元
-
批准年份:2023
-
负责人:唐铭
-
依托单位:
LIGHT-HVEM通路提升CAR-T细胞抗肿瘤活性的机制研究
-
批准号:82202031
-
项目类别:青年科学基金项目
-
资助金额:30万元
-
批准年份:2022
-
负责人:秦乐
-
依托单位:
LIGHT/TNFSF14通路对缺血再灌注肾损伤中细胞铁死亡影响的实验研究
-
批准号:
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2022
-
负责人:张克勤
-
依托单位:
气道上皮细胞经LIGHT/HVEM通路调控哮喘气道微环境内稳态的机制及干预研究
-
批准号:2020A151501040
-
项目类别:省市级项目
-
资助金额:10.0万元
-
批准年份:2020
-
负责人:史菲
-
依托单位:
MSCs通过免疫刺激因子LIGHT介导抗原缺失变异性乳腺癌的免疫效应及机制
-
批准号:LY21H160003
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2020
-
负责人:邹伟斌
-
依托单位:
Light助力中国科研团队提升国际影响力
-
批准号:--
-
项目类别:专项基金项目
-
资助金额:6万元
-
批准年份:2020
-
负责人:白雨虹
-
依托单位:
Shining light on the black hole mass distribution
-
批准号:12073029
-
项目类别:面上项目
-
资助金额:61.0万元
-
批准年份:2020
-
负责人:Roberto Soria
-
依托单位:
LIGHT(TNFSF14)诱导子痫前期的机制及其转化医学研究
-
批准号:2019JJ20035
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2019
-
负责人:王维
-
依托单位: